|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
7
|
|
gptkbp:bfsParent
|
gptkb:Geodon
|
|
gptkbp:activities
|
dopamine receptor antagonist
serotonin receptor antagonist
|
|
gptkbp:appointed_by
|
intramuscular injection
oral capsule
|
|
gptkbp:approves
|
gptkb:2001
gptkb:FDA
|
|
gptkbp:brand
|
Zeldox
|
|
gptkbp:category
|
gptkb:C
|
|
gptkbp:clinical_trial
|
Phase III trials
safety studies
long-term efficacy studies
|
|
gptkbp:contraindication
|
concurrent use of certain medications
severe heart conditions
history of QT prolongation
|
|
gptkbp:developed_by
|
gptkb:Pfizer
|
|
gptkbp:duration
|
12 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:formulation
|
suspension
oral tablet
injectable solution
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ziprasidone
|
|
gptkbp:ingredients
|
C21 H24 N4 OS
|
|
gptkbp:interacts_with
|
CY P3 A4 inducers
CY P3 A4 inhibitors
|
|
gptkbp:is_atype_of
|
N05 A E01
|
|
gptkbp:is_monitored_by
|
gptkb:weight
ECG
blood sugar
|
|
gptkbp:is_used_for
|
schizophrenia
bipolar disorder
|
|
gptkbp:legal_issue
|
prescription only
|
|
gptkbp:lifespan
|
5-10 hours
|
|
gptkbp:manager
|
oral
intramuscular
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:population
|
gptkb:Person
adults
elderly
|
|
gptkbp:premiered_on
|
1-2 hours
|
|
gptkbp:provides_information_on
|
gptkb:National_Institute_for_Health_and_Care_Excellence
gptkb:American_Psychiatric_Association
|
|
gptkbp:side_effect
|
nausea
restlessness
drowsiness
dry mouth
weight gain
|
|
gptkbp:traded_on
|
gptkb:Geodon
|
|
gptkbp:type_of
|
138105-41-3
|